<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04109742</url>
  </required_header>
  <id_info>
    <org_study_id>AAAS6731</org_study_id>
    <nct_id>NCT04109742</nct_id>
  </id_info>
  <brief_title>Curcumin for Pediatric Nonalcoholic Fatty Liver Disease</brief_title>
  <official_title>Curcumin for Pediatric Nonalcoholic Fatty Liver Disease: A Pilot Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Thorne Research Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Columbia University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-center, randomized, double-blinded, placebo-controlled, parallel treatment&#xD;
      groups phase 2a study of curcumin for pediatric nonalcoholic fatty liver disease (NAFLD).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      30 subjects ages 8-17y, with biopsy-proven NASH/NAFLD (≤ 730 days prior to registration and a&#xD;
      NAFLD Activity Score (NAS) of ≥3) and serum ALT at screening ≥ 50 IU/L at enrollment.&#xD;
      Eligible participants will receive curcumin 500 mg, 1.0 g or placebo for 24 weeks, randomized&#xD;
      1:1:1. The primary outcome of the study will determine whether 24 weeks of curcumin&#xD;
      supplementation compared to matching placebo improves measures of nonalcoholic fatty liver&#xD;
      disease (NAFLD) as determined by relative improvement in serum ALT from baseline. The&#xD;
      hypothesis is that curcumin will significantly decrease ALT relative to placebo in children&#xD;
      with NAFLD.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Lack of funding&#xD;
  </why_stopped>
  <start_date type="Actual">December 9, 2019</start_date>
  <completion_date type="Actual">April 22, 2020</completion_date>
  <primary_completion_date type="Actual">April 22, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The comparison of two different doses (500mg/qd and 1g/qd) of a phosphatidylcholine-curcumin complex supplement, to matching placebo</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Participants, investigators, clinical staff, and data monitoring committee will not have knowledge of the interventions assigned to individual participants.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in serum alanine aminotransferase (ALT) from baseline.</measure>
    <time_frame>24 weeks</time_frame>
    <description>ALT value in U/L</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Relative change in ALT compared to baseline ALT</measure>
    <time_frame>24 weeks</time_frame>
    <description>ALT value in U/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients achieving normalization of ALT</measure>
    <time_frame>24 weeks</time_frame>
    <description>ALT value in U/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum aspartate aminotransferase (AST)</measure>
    <time_frame>24 weeks</time_frame>
    <description>AST value in U/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum gamma-glutamyl transpeptidase (GGT)</measure>
    <time_frame>24 weeks</time_frame>
    <description>GGT value in U/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in ALT at 12 weeks compared to baseline ALT</measure>
    <time_frame>12 weeks</time_frame>
    <description>ALT value in U/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) compared to baseline</measure>
    <time_frame>24 weeks</time_frame>
    <description>is an equation which indicates the degree of insulin resistance, where higher scores equate to greater insulin resistance. HOMA-IR is calculated as fasting (Glucose (mmol/L) x insulin (pmol/L))/22.5. A HOMA-IR value &gt;2.0 in prepubertal children and &gt;2.6 in pubertal children, may be considered a warning sign for pediatricians to further investigate insulin resistance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Weight</measure>
    <time_frame>24 weeks</time_frame>
    <description>kilograms (kg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Waist circumference</measure>
    <time_frame>24 weeks</time_frame>
    <description>centimeters (cm)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Waist to Hip ratio</measure>
    <time_frame>24 weeks</time_frame>
    <description>ratio of the circumference of the waist to that of the hips. This is calculated as waist measurement divided by hip measurement (W ÷ H).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Body-mass Index Z- Score</measure>
    <time_frame>24 weeks</time_frame>
    <description>Body mass index z-scores is calculated using age, gender, height and weight and calculated using 2000 CDC Growth Charts for norms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum lipids compared to baseline</measure>
    <time_frame>24 weeks</time_frame>
    <description>lipid profiles</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in High Sensitivity C-Reactive Protein (hsCRP) compared to baseline</measure>
    <time_frame>24 weeks</time_frame>
    <description>serum marker of inflammation (mg/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Pediatric Quality of Life Inventory (PedsQL) Score scores compared to baseline</measure>
    <time_frame>24 weeks</time_frame>
    <description>Pediatric Quality of Life Inventory (PedsQL) version 4.0 is completed by both the child and parent/caregiver, and is composed of 23 items comprising 4 dimensions: Physical Functioning, Emotional Functioning, Social Functioning, and School Functioning. Scores are transformed on a scale from 0 to 100, with higher scores indicating better health-related quality of life. Physical Health Summary Score =Physical Functioning Scale Score. Psychosocial Health Summary Score = Sum of items over the number of items answered in the Emotional, Social, and School Functioning Scales.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Intrahepatic fat content and liver stiffness</measure>
    <time_frame>24 weeks</time_frame>
    <description>Hepatic fat content and liver stiffness will be measured by CAP and VCTE (Fibroscan®)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in frequency of adverse events compared to baseline</measure>
    <time_frame>24 weeks</time_frame>
    <description>Numbers of adverse events reported</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Plasma concentrations of curcumin and active metabolites from baseline to 24 weeks.</measure>
    <time_frame>Day 0 pre-dose and 1, 2, 4, 6, 8 hours post-dose; Day 14; Day 28; Day 84 and Day 168</time_frame>
    <description>Pharmacokinetic analysis</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in interleukin 6 (IL-6)</measure>
    <time_frame>24 weeks</time_frame>
    <description>cytokine protein involved in the pro-inflammatory and anti-inflammatory response</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in interleukin 8 (IL-8)</measure>
    <time_frame>24 weeks</time_frame>
    <description>cytokine protein involved in the pro-inflammatory and anti-inflammatory response</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in (TNF-a) Tumor Necrosis Factor alpha</measure>
    <time_frame>24 weeks</time_frame>
    <description>cytokine protein involved in the pro-inflammatory and anti-inflammatory response</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Plasminogen Activator Inhibitor (PAI-1)</measure>
    <time_frame>24 weeks</time_frame>
    <description>cytokine protein involved in the pro-inflammatory and anti-inflammatory response</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in adiponectin</measure>
    <time_frame>24 weeks</time_frame>
    <description>cytokine protein involved in the pro-inflammatory and anti-inflammatory response</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>NAFLD - Nonalcoholic Fatty Liver Disease</condition>
  <condition>NASH - Nonalcoholic Steatohepatitis</condition>
  <arm_group>
    <arm_group_label>Curcumin 500mg capsules</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dose will be 500mg daily phosphatidylcholine-curcumin complex supplement, orally for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Curcumin 1000mg capsules</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dose will be1g daily of phosphatidylcholine-curcumin complex supplement, orally for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo curcumin capsules</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Dose will be matching placebo capsules daily, orally for 24 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>phosphatidylcholine-curcumin complex supplement</intervention_name>
    <description>a dietary curcumin supplement given at two different doses</description>
    <arm_group_label>Curcumin 1000mg capsules</arm_group_label>
    <arm_group_label>Curcumin 500mg capsules</arm_group_label>
    <other_name>Meriva®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo curcumin capsule</intervention_name>
    <description>matching placebo to active curcumin capsules</description>
    <arm_group_label>Placebo curcumin capsules</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 8-17 years at initial screening interview&#xD;
&#xD;
          -  Histological evidence of NAFLD with or without fibrosis and a NAFLD activity score&#xD;
             (NAS) of ≥3, on a liver biopsy obtained no more than 730 days prior to enrollment&#xD;
&#xD;
          -  Serum ALT at screening ≥ 50 IU/L&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Significant alcohol consumption or inability to reliably quantify alcohol intake&#xD;
&#xD;
          -  Use of drugs historically associated with NAFLD (amiodarone, methotrexate, systemic&#xD;
             glucocorticoids, tetracyclines, tamoxifen, estrogens at doses greater than those used&#xD;
             for hormone replacement, anabolic steroids, valproic acid, other known hepatotoxins)&#xD;
             for more than 2 consecutive weeks in the past year prior to randomization&#xD;
&#xD;
          -  New treatment with vitamin E or metformin started in the past 90 days or plans to&#xD;
             alter the dose or stop over the next the 24 weeks. A stable dose is acceptable.&#xD;
&#xD;
          -  Prior or planned bariatric surgery&#xD;
&#xD;
          -  Uncontrolled diabetes (HbA1c 9.5% or higher within 30 days prior to enrollment)&#xD;
&#xD;
          -  Presence of cirrhosis on liver biopsy&#xD;
&#xD;
          -  Stage 2 Hypertension or &gt;140 systolic or &gt;90 diastolic at screening&#xD;
&#xD;
          -  Current daily use of nonsteroidal anti-inflammatory drugs (NSAIDs)&#xD;
&#xD;
          -  Platelet counts below 100,000 /mm3&#xD;
&#xD;
          -  Clinical evidence of hepatic decompensation (serum albumin &lt; 3.2 g/dL, international&#xD;
             normalized ratio (INR) &gt;1.3, direct bilirubin &gt;1.3 mg/dL, history of esophageal&#xD;
             varices, ascites, or hepatic encephalopathy)&#xD;
&#xD;
          -  Evidence of chronic liver disease other than NAFLD:&#xD;
&#xD;
               -  Biopsy consistent with histological evidence of autoimmune hepatitis&#xD;
&#xD;
               -  Serum hepatitis B surface antigen (HBsAg) positive.&#xD;
&#xD;
               -  Serum hepatitis C antibody (anti-HCV) positive.&#xD;
&#xD;
               -  Iron/total iron binding capacity (TIBC) ratio (transferrin saturation) &gt; 45% with&#xD;
                  histological evidence of iron overload&#xD;
&#xD;
               -  Alpha-1-antitrypsin (A1AT) phenotype/genotype ZZ or SZ&#xD;
&#xD;
               -  Wilson's disease&#xD;
&#xD;
          -  History of biliary diversion&#xD;
&#xD;
          -  History of kidney disease and/or estimated glomerular filtration rate (eGFR) &lt; than 60&#xD;
             mL/min/1.73 m2 using Schwartz Bedside GFR Calculator for Children isotope dilution&#xD;
             mass spectroscopy (IDMS)-traceable&#xD;
&#xD;
          -  Known Human Immunodeficiency Virus (HIV) infection&#xD;
&#xD;
          -  Active, serious medical disease with life expectancy less than 5 years&#xD;
&#xD;
          -  Active substance abuse including inhaled or injected drugs, in the year prior to&#xD;
             screening&#xD;
&#xD;
          -  Pregnancy, planned pregnancy, potential for pregnancy and unwillingness to use&#xD;
             effective birth control during the trial, breast feeding&#xD;
&#xD;
          -  Participation in any clinical/investigational trial within the prior 150 days and&#xD;
             during the study.&#xD;
&#xD;
          -  Any other condition which, in the opinion of the investigator, would impede compliance&#xD;
             or hinder completion of the study&#xD;
&#xD;
          -  Inability to swallow capsules&#xD;
&#xD;
          -  Known allergy to curcumin or any of its components&#xD;
&#xD;
          -  Failure of parent or legal guardian to give informed consent or subject to give&#xD;
             informed assent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joel E Lavine, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 23, 2019</study_first_submitted>
  <study_first_submitted_qc>September 27, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 30, 2019</study_first_posted>
  <last_update_submitted>September 21, 2021</last_update_submitted>
  <last_update_submitted_qc>September 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pediatric</keyword>
  <keyword>NAFLD - nonalcoholic fatty liver disease</keyword>
  <keyword>Curcumin</keyword>
  <keyword>Fatty liver</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Curcumin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

